Chronic pericarditis

Article written and reviewed by Dr Luca Moretti

The chronic pericarditis indicates inflammatory pericardial disease lasting more than three months. The temporal threshold, adopted in clinical classifications, does not by itself describe the anatomic substrate or the consequences for the heart. Inflammation, pain, and imaging activity may persist without impaired filling; in other cases adhesions and fibrosis predominate, or a fluid collection is present. To understand the meaning of chronicity, inflammatory activity, pericardial morphology, and physiology must therefore be specified separately.

The incessant pericarditis describes absence of remission and may become chronic when it exceeds three months. recurrent pericarditis instead includes attacks separated by remissions: a history lasting years does not necessarily mean continuous inflammation. constrictive pericarditis is defined by impaired filling caused by pericardial constraint, not by duration. These categories may overlap, but should not be used as synonyms.

An isolated chronic effusion likewise does not demonstrate active pericarditis. Fluid may persist because of altered drainage, systemic disease, or noninflammatory causes and requires its own evaluation. This distinction has concrete therapeutic consequences: anti-inflammatory drugs and immunomodulators may be appropriate when an inflammatory target exists, whereas they are not an automatic treatment for every effusion present for months. No single prevalence estimate for chronic pericarditis is transferable to all populations because studies and registries include different phenotypes and often select patients already referred to specialist centers.

Etiology, persistence factors, and pericardial remodeling

Causes of chronicity include both persistence of the stimulus and a host response that continues after the trigger disappears. Tuberculosis and other inadequately controlled infections may sustain prolonged disease; in bacterial forms, an organized collection or insufficient drainage may maintain the process. The likelihood of these conditions depends on epidemiology, immune status, and clinical history. A long course does not justify assuming a viral cause, nor excluding infection simply because fever and pain were attenuated by corticosteroids.

In autoimmune diseases the pericardium may remain involved as long as systemic activity persists. Lupus, rheumatoid arthritis, and other inflammatory conditions produce different patterns according to associated organs and treatment response. Autoinflammatory syndromes may instead sustain dysregulation of the innate response, sometimes with febrile episodes and polyserositis. The two components are not necessarily alternatives: local injury, innate immunity, and adaptive immunity interact. An idiopathic definition remains a clinical conclusion proportionate to the investigation performed, not the name of an already demonstrated immune mechanism.

The iatrogenic injury includes consequences of cardiac surgery, procedures, radiotherapy, and some drugs. After a procedure, residual blood, inflammation, and tissue organization may contribute to adhesions; a post-cardiac injury syndrome may maintain an immune-mediated component. Radiotherapy can simultaneously affect pericardium, myocardium, valves, and coronary arteries, making an exclusively pericardial interpretation of symptoms inadequate. Neoplastic infiltration and obstruction of lymphatic drainage may be associated with inflammation but can also produce collections without a typical pericarditic syndrome. Uremia is another setting in which control of the underlying disease is crucial.

The factors promoting persistence include incomplete treatment, tolerability limitations, interactions, excessively early tapering, and failure to recognize the cause. These elements should be distinguished from factors that increase the likelihood of a specific etiology, such as immunosuppression, tuberculosis exposure, or previous thoracic irradiation. An elevated CRP or a thickened pericardium are instead disease findings, not causes. Corticosteroid dependence also mainly describes clinical and therapeutic behavior: by itself it identifies neither an infection nor a genetic defect.

Within the tissue, mesothelial and microvascular injury causes exudation, cellular recruitment, and fibrin deposition. If the stimulus resolves, clearance of exudate and repair may restore sliding of the surfaces; if it continues, granulation tissue may organize into adhesions and extracellular matrix. Macrophages, lymphocytes, fibroblasts, and mesothelial cells contribute in different proportions according to cause and phase. Collagen deposition and matrix reorganization alter elastic properties, but there is no obligatory sequence leading every chronic inflammation to constriction.

The interleukin-1 axis is relevant in some persistent or recurrent phenotypes. Damage signals promote activation of innate immunity; the NLRP3 inflammasome may contribute to maturation of interleukin-1 beta through caspase-1. These mechanisms explain part of the rationale for colchicine and targeted therapies, without providing a universal explanation for neoplasia, infections, uremia, and radiation injury. Experimental evidence on inflammatory circuits is not equivalent to demonstrating the same defect in every patient. In established fibrosis, moreover, suppressing a cytokine does not necessarily remove an already formed mechanical constraint.

The fibrosis may involve the layers diffusely or regionally; adhesions may obliterate portions of the cavity and compartmentalize fluid. Calcification is a possible outcome of prolonged injury, but is neither necessary for constriction nor a measure of its severity. Increased thickness may also reflect edema, infiltrate, or still-reversible organization. Morphology and function must therefore be correlated: a calcified plaque without filling abnormalities has a different significance from a minimally thickened pericardium that is rigidly adherent to the heart.

The pathophysiologic consequences occur on several levels. Inflammation of sensitive structures causes pain; altered fluid turnover causes effusion; loss of compliance may generate constriction. If venous pressures remain chronically elevated, hepatic and renal congestion, edema, and sometimes enteric protein loss develop. If a compressive collection predominates, cardiac output may fall because filling is impaired. The contribution of associated myocardial injury should be sought, especially after radiotherapy or in systemic diseases, because it changes prognosis and expected benefit from therapy directed only at the pericardium.

Clinical manifestations and longitudinal assessment

The history should reconstruct the temporal course more precisely than the phrase 'pain for months'. Onset, true remissions, periods of partial improvement, flares, and relation to therapies are defined. It is useful to retrieve ECGs, inflammatory markers, and images from the first episode and subsequent follow-up. A persistent collection with disappearance of pain may represent a different outcome from continuous inflammation; a history of separated attacks should be described as recurrent even if it is long overall. The timeline is therefore a diagnostic tool, not merely an administrative datum.

In the active inflammatory component respiratory or positional pain, low-grade fever, fatigue, and malaise may persist. Pain may become less characteristic and coexist with chest-wall or digestive disorders, especially after prolonged treatment. Variation with breathing or relief from an NSAID supports a hypothesis but does not confirm it in isolation. A new quality of symptoms, sudden onset, or appearance with exertion requires reassessment of ischemic, vascular, and pulmonary causes even in someone with an established pericardial diagnosis.

When a persistent effusion predominates, the patient may be asymptomatic or report dyspnea, chest pressure, cough, and reduced exercise tolerance. Severity depends more on the rate of accumulation and hemodynamic consequences than on duration. A slowly accommodated collection may become large without shock; a rapid change in the same collection may instead cause deterioration. Absence of pain is therefore not a sufficient marker of safety, but neither does echocardiographic size alone justify diagnosing tamponade.

The constrictive component often presents with symptoms of congestion: dependent edema, increased abdominal circumference, ascites, fullness, early satiety, and reduced exercise capacity. Some patients are initially investigated for liver or gastrointestinal disease. Dyspnea may be present without marked pulmonary congestion, and ejection fraction may remain preserved. Weight loss and reduced muscle mass may be masked by increased extracellular fluid. The combination of ascites and jugular venous distension therefore merits specific cardiac evaluation.

Physical examination assesses venous pressure, perfusion, rhythm, and nutritional status, in addition to friction rub and respiratory signs. Kussmaul's sign, meaning failure of jugular venous pressure to fall or its increase during inspiration, points toward difficulty accommodating venous return but is not specific to constriction. An early diastolic pericardial knock may indicate abrupt cessation of filling. Pulsus paradoxus, hypotension, and tachycardia may suggest a compressive collection. Absence of these signs does not eliminate disease at an early or partially treated stage.

The search includes extracardiac manifestations consistent with a cause: arthritis, rash, mucosal lesions, lymphadenopathy, prolonged fever, signs of kidney disease, and a history of neoplasia. Medication history includes cumulative doses, withdrawal attempts, and interactions. Bruising, proximal weakness, weight gain, hyperglycemia, or digestive disorders may represent treatment cost rather than worsening of the pericardium. These components should be described separately because treating an iatrogenic symptom with greater immunosuppression can reinforce a false impression of refractoriness.

Functional assessment considers independence and quality of life, work activity, sleep, and the ability to maintain a physically active life. A disease with low probability of fatal outcomes may nevertheless be highly limiting. Conversely, a person with little pain may have important progressive congestion. Follow-up frequency and treatment goals should therefore depend on the entire phenotype, not pain intensity alone. During follow-up, comparison with the previous state helps distinguish true recovery, adaptation to limitations, and development of new injury.

Investigations, diagnostic criteria, and differential diagnosis

Diagnosis of chronicity requires a duration longer than three months, but this threshold does not replace demonstration of the underlying disease. There are no independent criteria that turn prolonged pain or a calcified pericardium into active inflammatory pericarditis. It should be specified whether inflammation, a structural sequela, or an isolated effusion is being documented. Previous reports are re-examined for the original evidence because a label repeated in medical records may persist even when the findings that motivated it are no longer present.

For the inflammatory component, the 2025 ACC pathway is applicable, associating a suggestive clinical presentation such as pleuritic pain or an equivalent with at least one additional finding. Duration beyond three months is specified separately. Findings must be interpreted in context: a high CRP from an extracardiac infection or a stable effusion without other evidence do not automatically demonstrate chronic pericardial activity.

Additional findings accompanying a compatible clinical presentation in the diagnosis of pericarditis according to the 2025 ACC pathway.

• Documented pericardial friction rub.
• Characteristic electrocardiographic abnormalities.
• Elevation of inflammatory markers.
• New or increased pericardial effusion.
• Evidence of pericardial inflammation on imaging.

The ECG assesses changes from baseline, rhythm, conduction, and possible signs of myocardial involvement. Residual repolarization abnormalities do not necessarily constitute evidence of continuous activity. CRP, complete blood count, renal and hepatic function, and electrolytes are measured, adding troponin when myocardial injury is suspected. A normal CRP may reflect pharmacologic control or a local response poorly expressed in blood; its meaning depends on the history. Albumin, urinalysis, and other parameters may instead clarify edema, protein loss, and systemic consequences.

The Doppler echocardiography is central to distinguishing fluid, ventricular function, and filling abnormalities. The report describes size and distribution of the collection, any loculations, chamber compression, and respiratory signs of interdependence. In forms suspicious for constriction, septal motion, annular velocities, atrioventricular flows, and hepatic venous flow are assessed. A dilated inferior vena cava indicates congestion but does not identify its cause. Even a normal ejection fraction does not exclude severe diastolic limitation because it does not directly measure the heart's capacity to receive blood.

The magnetic resonance imaging contributes to tissue characterization and assessment of reversibility. Water-sensitive sequences assess edema, whereas late gadolinium enhancement, or LGE, documents a tissue abnormality that may accompany inflammation, vascularity, and remodeling. LGE alone may persist and should not be used as an automatic instruction to intensify treatment. Its greatest value comes from concordance with edema, clinical findings, and course. Magnetic resonance imaging may also recognize myocardial injury and show, during free breathing, septal changes consistent with constrictive physiology.

The computed tomography clearly defines calcifications, anatomy, masses, adhesions suggested by the context, and distribution of collections, and is useful for surgical planning. It does not by itself demonstrate the severity of constriction. A thick pericardium may not impede filling, and one without increased thickness may be functionally constraining. Catheterization is reserved for cases in which hemodynamic distinction remains uncertain or could change an important decision. Biopsy and fluid analysis instead have mainly etiologic purposes and should be motivated by a concrete clinical question.

The differential diagnosis includes restrictive cardiomyopathy, right-sided heart failure, tricuspid valve disease, pulmonary hypertension, and hepatic or renal disease. In isolated effusion, hypothyroidism and noninflammatory drainage abnormalities should also be considered. Prolonged pain includes musculoskeletal, pleural, and esophageal causes. Pericardial and myocardial disease may coexist, especially after radiotherapy: insisting on a single explanation risks underestimating complexity. The diagnostic conclusion should indicate which component is demonstrated, which remains probable, and which test may resolve the remaining uncertainty.

Definition of cause, activity, and organ consequences

Etiologic investigation is guided by change in phenotype. Development of persistent fever, an enlarging collection, weight loss, or lymphadenopathy requires reassessment even if the initial episode was considered idiopathic. Conversely, indefinitely repeating panels that were already negative in an unchanged clinical picture does not necessarily improve accuracy. Evaluation starts from the tests actually performed, their sensitivity, and the time they were obtained. A culture obtained after antibiotics or CRP measured while taking steroids answers different questions from samples collected before treatment.

The search for infection integrates epidemiology, immunosuppression, imaging, and appropriate samples. A positive immunologic test for tuberculosis does not demonstrate pericardial localization; cultures, molecular testing, and histology, when available and indicated, may provide more direct evidence. In collections suspicious for bacterial infection, the issue is not only identifying the organism but achieving effective source control. A long history of immunomodulatory therapy may attenuate manifestations and increase the risk of opportunistic infections, requiring safety to be reconsidered before further escalation.

For systemic diseases investigations are selected on the basis of organs and clinical signs. Autoantibodies, complement, urinalysis, and rheumatologic assessment may clarify an autoimmune picture; suspected autoinflammatory disease may require reconstruction of attacks and family history, sometimes with genetic counseling. An isolated antibody finding or an uncertain variant should not replace phenotypic concordance. In oncology patients, cytology, imaging, and assessment of current treatment help distinguish infiltration, treatment reaction, and independent causes.

Measurement of residual activity is distinct from measurement of damage. Fever, CRP, edema, and dynamic changes suggest a component treatable with anti-inflammatory drugs; calcifications, adhesions, and established constrictive physiology may indicate a structural problem. The two aspects may coexist. Serial assessment makes it possible to determine whether reduction in inflammation is accompanied by improved filling. If biomarkers normalize but congestion remains, the clinical problem cannot be considered resolved.

The hepatorenal injury is analyzed while recognizing multiple mechanisms. Congestion raises renal venous pressure and may reduce filtration; NSAIDs, dehydration, and underlying kidney disease may contribute. In the liver, chronic congestion and fibrosis may produce biochemical abnormalities and ascites, while primary liver disease may coexist. Hypoalbuminemia may result from reduced synthesis, renal loss, malnutrition, or protein-losing enteropathy. Attributing it generically to pericarditis would prevent selection of appropriate treatment and correct estimation of operative risk.

A complete definition includes therapeutic risk and functional reserve: age, frailty, nutritional status, pulmonary comorbidities, rhythm, and myocardial function. Before a biologic, appropriate infectious and laboratory assessment is planned; before surgery, anatomy and possible associated cardiac lesions are characterized. The decision does not arise from the word chronic, but from the intersection between a correctable mechanism and the ability to tolerate treatment. Follow-up should therefore specify the goal being pursued: inflammatory remission, stability of a collection, reduction of congestion, or correction of an irreversible constraint.

Treatment according to phenotype and prognosis

In active inflammatory disease, adequate anti-inflammatory therapy remains appropriate even beyond three months, provided the indication is confirmed and safety is reassessed. Aspirin or an NSAID is selected according to renal function, bleeding risk, ischemic disease, and tolerability. Usual adult regimens include ibuprofen 600-800 mg every eight hours or aspirin 750-1,000 mg every eight hours during the active phase, followed by tapering after control is achieved. Chronicity does not justify maintaining them indefinitely at full dose or combining several NSAIDs when response is inadequate.

The colchicine is useful in persistent or recurrent inflammatory phenotypes. Doses of 0.5 mg daily for body weight below 70 kg and 0.5 mg twice daily at 70 kg or above are often used, with adjustments for organ function, age, and interactions. In incessant or recurrent courses, treatment generally lasts at least six months and is adapted to stability. Randomized evidence on recurrence prevention should not, however, be extrapolated to a noninflammatory chronic effusion. Significant diarrhea, muscle weakness, and interactions with CYP3A4 or P-glycoprotein inhibitors require prompt review of the prescription.

The corticosteroids may be indicated for autoimmune disease or when other options are inadequate, but they are not an automatic response to long duration. Use should consider infection risk and, when appropriate, favor low or moderate doses, often prednisone 0.2-0.5 mg/kg/day. Tapering occurs after clinical and objective control, slowly especially at low doses and after prolonged exposure. Fatigue and myalgia during reduction may also be due to adrenal suppression. The goal is not only to prevent a flare but to reduce the cumulative burden of a potentially harmful therapy.

In phenotypes with documented inflammatory activity and insufficient control, interleukin-1 blockade may be considered. Anakinra and rilonacept have important evidence in selected recurrent forms, especially those resistant to colchicine or dependent on steroids. AIRTRIP and RHAPSODY did not indiscriminately study every pericardial disease present for more than three months: selection must respect this difference. Before treatment, relevant infections are excluded and monitoring, vaccinations, and reduction of previous therapies are planned. A rapid response does not equal permanent cure, and discontinuation requires an individualized strategy.

Azathioprine, intravenous immunoglobulin, and other forms of immunomodulation have a selective role in refractory forms or systemic diseases. Azathioprine acts slowly and does not replace control of an acute attack; immunoglobulins are supported mainly by observational experience. Choice should depend on the clinical target, not on a desire to eliminate any residual imaging abnormality. When evidence of inflammation is lacking, the strategy should be reconsidered before introducing a more powerful drug. Mechanically relevant fibrosis requires reasoning different from still-reversible inflammation.

In an isolated chronic effusion management depends on cause, symptoms, and hemodynamic impact. An idiopathic, stable collection without inflammation or compression may be observed in selected patients; drainage is not mandatory merely because the effusion has been present for months. The cohort by Imazio and colleagues on large chronic idiopathic effusions showed that spontaneous regression and conservative management are possible, but because it is observational it does not demonstrate that observation is always superior. Tamponade, suspected infection, suspected neoplasia, or symptoms attributable to the collection may change management.

In inflammatory constriction that is potentially reversible, a trial of medical therapy with scheduled reassessment may avoid unnecessary surgery. Inflammation, venous pressure, functional capacity, and Doppler findings are assessed together. Established, symptomatic, nonreversible constriction instead requires evaluation for pericardiectomy. Diuretics relieve congestion but do not remove the constraint and should be dosed without excessively reducing preload. Prolonged delay of necessary correction may worsen malnutrition and organ damage, increasing the risk of the very operation one is trying to avoid.

The etiologic treatment remains a priority: antimycobacterial regimens for tuberculosis, antibiotics and source control for bacterial infections, adjustment of dialysis in uremic forms, and oncologic management in neoplastic disease. In radiation injury, the benefit of a pericardial procedure also depends on myocardium, valves, and coronary arteries. Intense exercise is limited during inflammatory activity or instability; after control, recovery is gradual and accounts for any myocardial involvement. A chronic diagnosis by itself does not justify immobility or permanent exclusion from an active life.

The monitoring is calibrated to risk. During treatment changes, closer follow-up is needed; during stability, intervals may be longer while maintaining precise goals. Activity, collections, function, and toxicity are monitored, avoiding both pursuit of tests without decision-making value and discontinuation of follow-up after pain alone has disappeared. Prognosis is generally favorable in idiopathic forms without hemodynamic damage, but changes with specific infection, neoplasia, constriction, and associated myocardial disease. Duration remains a descriptor, not an independent measure of irreversibility.

Complications and long-term consequences

The persistent constriction is a possible outcome, especially in some etiologies, but is not inevitable. Risk after idiopathic or presumed viral pericarditis is much lower than in bacterial and tuberculous forms. Development of congestion should be recognized before it is attributed entirely to liver, kidney, or inactivity. Even transient constriction may cause important symptoms and requires surveillance; potential reversibility does not mean absence of consequences during the active phase.

The tamponade may complicate a chronic collection if the rate of accumulation, pressure, or adaptive capacity changes. Signs of deterioration include increasing dyspnea, tachycardia, hypotension, oliguria, and hypoperfusion, with less classic presentations in compartmentalized collections. Drainage is decided on the clinical and echocardiographic picture, not duration alone. In the effusive-constrictive form, fluid and the constraint of the visceral layer both contribute to obstruction; after evacuation, a filling abnormality may therefore persist and require further treatment.

The chronic congestion may cause hepatic injury, reduced renal function, refractory ascites, and nutritional impairment. Elevated venous pressure interferes with organ drainage and perfusion; intestinal stasis and lymphatic dysfunction may contribute to protein loss. Hypoalbuminemia and sarcopenia reduce functional reserve and complicate surgery. Fluid-related weight gain may conceal true weight loss, making it useful to follow both volume status and the patient's body composition and functional capacity.

The atrial arrhythmias may accompany atrial dilation, elevated filling pressure, or associated heart disease. Loss of atrial contraction and an inappropriate rate can worsen filling in an already constrained system. Any anticoagulation is decided according to indication and individual risk, simultaneously considering effusion, bleeding, and planned procedures. A new rhythm disorder should not be dismissed as a simple effect of anxiety or pain, but neither should it automatically be attributed to pericarditis in the absence of a comprehensive cardiac assessment.

The cumulative toxicity may become a dominant component: gastrointestinal and renal injury from NSAIDs, colchicine toxicity in predisposed settings, metabolic, bone, and infectious complications of steroids, and specific risks of immunomodulation. Prevention includes periodic review of the indication, the lowest effective dose, and relevant monitoring. A new comorbidity may make a previously well-tolerated regimen hazardous. Continued treatment should therefore be justified by current benefit, not merely by difficulty encountered during a withdrawal attempt far in the past.

The limitation of daily life results from the sum of symptoms, deconditioning, adverse effects, and uncertainty. An effective care program should provide understandable criteria for stability, recovery methods, and warning signs requiring urgent reassessment. New pain, syncope, worsening dyspnea at rest, persistent fever, or increasing congestion require attention. During stable periods, recovery of sleep, work, and movement completes biological control. Distinguishing what remains inflammatory from what is structural or iatrogenic remains the prerequisite for limiting long-term harm.

Bibliography
1. Schulz-Menger J et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. European Heart Journal. 2025;46(40):3952-4041.
2. Wang TKM et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Diagnosis and Management of Pericarditis: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2025;86(25):2691-2719.
3. Klein AL et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. JACC: Cardiovascular Imaging. 2024;17(8):937-988.
4. Adler Y et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36(42):2921-2964.
5. Roberts WC. Pericardial heart disease: its morphologic features and its causes. Proceedings (Baylor University Medical Center). 2005;18(1):38-55.
6. Mauro AG et al. The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches. JACC: Basic to Translational Science. 2021;6(2):137-150.
7. Imazio M et al. Outcomes of idiopathic chronic large pericardial effusion. Heart. 2019;105(6):477-481.
8. Imazio M et al. Risk of constrictive pericarditis after acute pericarditis. Circulation. 2011;124(11):1270-1275.
9. Welch TD et al. Echocardiographic diagnosis of constrictive pericarditis: Mayo Clinic criteria. Circulation: Cardiovascular Imaging. 2014;7(3):526-534.
10. Brucato A et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA. 2016;316(18):1906-1912.
11. Klein AL et al. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. New England Journal of Medicine. 2021;384(1):31-41.
12. Imazio M et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. The Lancet. 2014;383(9936):2232-2237.
13. Mayosi BM et al. Tuberculous pericarditis. Circulation. 2005;112(23):3608-3616.